MBX Biosciences IncMBX
Price$56.55

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$104.3MTTM through 30 Jun 2026
Free Cash Flow -$85.2MTTM through 30 Jun 2026

Margins

Current

Returns

-27.8%ROE
-22.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio24.62x
Net Debt-$373.1Mnet cash position
Cash & Equivalents$54.1M

Quality Metrics

Altman Z-Score67.22
Piotroski F-Score1 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS-$2.37TTM
'23'24'25
FY2025: $-2.38

Dividend

No dividend

Capital Allocation

R&D Spend$88.5M

Segment Performance

SegmentRevenueYoYOutlook
Single Segment$0
View details

The company expects to continue incurring significant research and development expenses as it initiates Phase 3 trials for canvuparatide and advances its obesity pipeline.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.